Can anticoagulant treatment be tailored with biomarkers in patients with venous thromboembolism?

J Thromb Haemost. 2006 Jun;4(6):1206-7. doi: 10.1111/j.1538-7836.2006.01931.x.
No abstract available

Publication types

  • Comment

MeSH terms

  • Anticoagulants / adverse effects
  • Anticoagulants / therapeutic use*
  • Biomarkers / blood
  • Factor VIII / metabolism
  • Fibrin Fibrinogen Degradation Products / metabolism
  • Hemorrhage / etiology*
  • Humans
  • Risk Factors
  • Secondary Prevention
  • Thromboembolism / blood
  • Thromboembolism / prevention & control*
  • Venous Thrombosis / blood
  • Venous Thrombosis / prevention & control*
  • Warfarin / adverse effects
  • Warfarin / therapeutic use*

Substances

  • Anticoagulants
  • Biomarkers
  • Fibrin Fibrinogen Degradation Products
  • fibrin fragment D
  • Warfarin
  • F8 protein, human
  • Factor VIII